Bambusa’s lead candidate BBT001 is being investigated for dermatologic indications. Credit: kirisa99 via Getty Images. US-based startup Bambusa Therapeutics has secured $90m in Series A financing to ...
Bambusa Therapeutics has raised about $90 million to build out a pipeline of next-gen bispecific antibodies targeting immunological and inflammatory (I&I) conditions. New investor RA Capital ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback